Sanofi

Stocks

SAN

FR0000120578

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-07-20 EDT			5-day change	1st Jan Change
76.91 ^EUR	-0.56%		+0.89%	-7.02%

07-20	European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading	MT
07-20	Eli Lilly May Raise Stake in Scribe Therapeutics to 10.9% Through IPO	MT

Transcript : Sanofi - Special Call

Published on 12/16/2025 at 01:20 pm EST - Modified on 12/16/2025 at 09:50 pm EST

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Thomas Larsen (Executives)

Good afternoon and good morning, depending on where you are, and welcome to the Sanofi's first year-end late-stage pipeline review. I'm Thomas Kudsk Larsen

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Sanofi

07-20	European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading	MT
07-20	Eli Lilly May Raise Stake in Scribe Therapeutics to 10.9% Through IPO	MT
07-20	Eli Lilly May Raise Stake in Scribe Therapeutics to 10.9% Stake Through IPO	MT
07-20	Scribe Therapeutics to Sell 7.15 Million Shares at $13-$15 Each in IPO	DJ
07-17	Sanofi strengthens its research alliance with Aqemia
07-17	Aqemia and Sanofi Expand Research Collaboration	CI
07-16	Merck gets US FDA nod for first-in-its-class oral cholesterol drug	RE
07-14	European Equities Traded in the US as American Depositary Receipts Rise Tuesday	MT
07-14	Where would AI lead Pharma in the long run?
07-14	AlphaValue/Baader Europe Downgrades Sanofi to Add, Trims PT	MT
07-13	SANOFI : UBS reiterates its Neutral rating	ZD
07-13	EXECUTIVE CHANGES: Rank Group confirms interim CEO Harris as permanent	AN
07-10	Sanofi Receives Fda Approval for Subcutaneous Sarclisa Escena Administered Via On-Body Injector	CI
07-10	Sanofi Wins US FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma	MT
07-10	The FDA Authorizes an Innovative Version of Sanofi's Sarclisa